The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes

Abstract

Varying concentrations of octreotide acetate (Sandostatin^®) and diamorphine hydrochloride were prepared and stored in polypropylene syringes at 37°C in the dark. The solutions were analysed for octreotide acetate content using a validated HPLC method at regular intervals over a 48-h period. The results indicate that octreotide acetate remains stable in the presence of diamorphine hydrochloride at 37°C for 24 h. In addition, the solutions prepared maintained their clarity, with no signs of precipitation upon visual examination under normal light conditions.

Keywords

compatability diamorphine drug combinations drug stability octreotide

Get full access to this article

View all access options for this article.

References

Khoo D , Riley J , Waxman J . Control of emesis in bowel obstruction in terminally ill patients. Lancet 1992; 339: 375–376.

Mercadante S , Maddaloni S . Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage 1992; 7: 496–498.

Mercadante S , Caraceni A , Simonette M . Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 7: 295–299.

Mercadante S , Kargar J , Nicolosi G . Octreotide may prevent definitive intestinal obstruction. J Pain Symptom Manage 1997; 13: 352–355.

Reynolds JEF ed. Martindale: the extra pharmacopoeia, 31st edn. London: The Royal Pharmaceutical Society, 1996: 1289.

Mercadante S . The role of octreotide acetate in palliative care. J Pain Symptom Manage 1994; 9: 406–411.

Riley J , Fallon M . Octreotide in terminal malignant obstruction of the gastrointestinal tract. Eur J Palliat Care 1994; 1: 23–25.

Ripley RG , Ritchie DJ , Holstad SG . Stability of octreotide acetate in polypropylene syringes at 5 and -20°C. Am J Health Sys Pharm 1995; 52: 1910–1911.

Kyaterekera N , Tettey JN , Skellern GG et al. Stability of octreotide in the presence of diamorphine hydrochloride. J Pharm Pharmacol 1997; 49: 8.

10.

Kyaterekera N , Tettey JN , Skellern GG et al. HPLC determination of octreotide acetate in compound formulations of Sandostatin® and diamorphine hydrochloride. J Pharm Biomed Anal 1999; 21: 327–330.

11.

Omar OA , Hoskin PJ , Johnston A , Hanks GW , Turner P . Diamorphine stability in aqueous solution for subcutaneous infusion. J Pharm Pharmacol 1989; 41: 275–277.